TotalMarketCap

Summit Therapeutics

SMMTNasdaq United StatesHealth CareBiotechnology: Pharmaceutical Preparations

Market cap

$11.513 B

$14.40 -10.98%

Close of 6 Nov 2026

As of 6 Nov 2026, Summit Therapeutics (SMMT) has a market capitalization of $11.5B. Market cap measures the value of outstanding equity at market prices; company totals combine applicable share classes. Prices and market caps come from Nasdaq, with financial fundamentals from SEC filings. See sources and calculation details.

Revenue

$0.00

#3616 by revenue

Earnings

-$1.08B

Loss-making

Shares outstanding

799,763,918

Latest filing cover page

P/E ratio

—

Cap ÷ net income

Biotechnology: Pharmaceutical Preparations, ranked by market cap

All 498 →
  1. #29Dr Reddys LaboratoriesRDY$12.1B
  2. #30Elanco Animal HealthELAN$11.8B
  3. #31Summit TherapeuticsSMMT$11.5B
  4. #32Biomarin PharmaceuticalBMRN$10.9B
  5. #33Madrigal PharmaceuticalsMDGL$9.30B

What if Summit Therapeutics were worth as much as…

Open the what-if tool →

Gold $28.2T

$35,306.51

Per share 2,453× higher

Bitcoin $1.53T

$1,910.37

Per share 133× higher

Apple $5.02T

$6,271.58

Per share 436× higher

Or at a round number

$20.0B$50.0B$100.0B$200.0B

Where these numbers come from

Share counts and financials for Summit Therapeutics are taken from its own SEC filings via EDGAR: public record, not an estimate. Market cap is shares outstanding multiplied by the latest close. Read the methodology.